Drug Profile

Research Programme: factor XIIa inhibitors - Rockefeller University

Latest Information Update: 28 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rockefeller University
Developer Bridge Medicines; Rockefeller University
Class Anti-inflammatories; Skin disorder therapies; Small molecules; Vascular disorder therapies
Mechanism of Action Factor XIIa inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2024 No recent reports of development identified for research development in Hereditary-angioedema in USA
28 Oct 2024 No recent reports of development identified for research development in Inflammation in USA
21 Sep 2020 Bridge Medicines and Rockefeller University enters into a licensing agreement to develop a series of small molecule inhibitors of activated factor XIIa for Inflammation and Hereditary angioedema

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com